#ASCO21: EQRx's cheaper EGFR drug busts Iressa in head-to-head test, and a US filing could be right down the road

Kyle Blankenship

With a slew of pricey oncology drugs dominating the market, disruptor EQRx has pledged to launch its own discounted competitors to bring the fight to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASCO21: EQRx's cheaper EGFR drug busts Iressa in head-to-head test, and a US filing could be right down the road

Kyle Blankenship

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A

FDA approves Ionis’ treatment for a rare metabolic disorder

#AS­CO21: EQRx's cheap­er EGFR drug busts Ires­sa in head-to-head test, and a US fil­ing could be right down the road

Kyle Blankenship

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

#ASCO21: EQRx's cheaper EGFR drug busts Iressa in head-to-head test, and a US filing could be right down the road

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A

FDA approves Ionis’ treatment for a rare metabolic disorder